38 results about "Theaflavine" patented technology

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention belongs to the technical field of medicines, and particularly provides a novel application of a theaflavin compound in preparation of a product for inhibiting dipeptidyl peptidase-4 (DPP-4), and the theaflavin compound is one or more of theaflavin-3-gallate (TF2A), theaflavin-3 '-digallate (TF3) and theaflavin (TF). The research systematically proves that TF2A, TF3 and TF have new application of inhibiting DPP-4 for the first time: in-vitro enzymology and fluorescence experiments show that theaflavin can inhibit DPP-4 and interact with DPP-4, and molecular docking further shows possible binding configuration and key action sites of theaflavin. In vivo, the activity of DPP-4 in serum and different tissues of high-fat diet mice can be reduced, serum glucagon-like peptide-1 (GLP-1) can be up-regulated, and glycometabolism and inflammatory phenotype can be improved. Therefore, the theaflavin compound disclosed by the invention can be applied to preparation of products for inhibiting DPP-4, and has a good development prospect.

The application provides a pig fattening period feed additive and a compound feed containing an amino acid chelate and belongs to the technical field of feeds.The pig fattening period feed additive comprises the following components in percentage by mass: 37-45% of an amino acid chelate, 24-28% of a compound multivitamin, 8-12% of betaine, 5-10% of theaflavin and 10-15% of a compound enzyme.The betaine and theaflavin can synergistically improve muscle composition and fat absorption, promote fat decomposition of pigs and increase lean meat percentage of pig carcasses.The pig fattening period feed additive is nutritionally comprehensive and balanced, the components are reasonably matched, can effectively increase the growth rate, daily weight gain and lean meat percentage of pigs, is a safe and efficient pig fattening period feed additive and solves the problems of slow growth and low lean meat percentage of pigs in the fattening period.

Provided is a composition comprising 20-40 parts by weight of cordyceps militaris powder, 3-25 parts by weight of theaflavins, and 1.25-4.2 parts by weight of astaxanthin, which is a whitening composition or a melanin synthesis signal antagonizing composition. The composition can be used as a main ingredient in whitening food or health food.

The invention discloses a preparation method of high-activity theaflavin. The method sequentially comprises the following steps: preparation and enzyme purification of tea powder, ultrasonic-assisted enzymolysis, oil-water double-liquid phase step type fermentation and online extraction, chromatographic column separation and purification, and membrane concentration and drying. According to the method, an oil-water double-liquid-phase enzymatic oxidation system is constructed, the fermentation process and the extraction process are coupled, the characteristic that the target product theaflavin-3, 3 '-digallate has a higher partition coefficient in an organic phase is utilized, in-situ separation and enrichment in the reaction process are achieved, and product degradation is avoided. In combination with a subsequently adopted specific chromatographic separation technology, the content of the high-activity TF3 monomer in the product is finally successfully increased to 50% or above of the total theaflavin monomer, and the biological activity of the product is improved.

This invention provides an immune-enhancing theaflavin composition, its preparation method, and its application, belonging to the field of biotechnology. The composition comprises *Schlumbergera truncata* extract peptides, theaflavins, and *Spatholobus suberectus* kernel extract. The *Schlumbergera truncata* extract peptides contain peptides between 1000 Da and 3000 Da obtained through trypsin hydrolysis of *Schlumbergera truncata*. This invention employs a special method to obtain *Schlumbergera truncata* extract peptides and *Spatholobus suberectus* kernel extract, and designs a more efficient compounding ratio of *Schlumbergera truncata* extract peptides, theaflavins, and *Spatholobus suberectus* kernel extract. The combined use of these three components exhibits excellent immune-enhancing effects, significantly improving the efficacy compared to using theaflavins alone and effectively enhancing the utilization of theaflavins.

The invention relates to application of theaflavin as a UGP2 inhibitor and application of theaflavin in preparation of a medicine for preventing and / or treating hepatocellular carcinoma, and belongs to the technical field of biology. According to the invention, the monomeric compound theaflavin derived from a natural product can be used as a UGP2 direct targeting inhibitor for the first time, and is used for preparing a liver cancer treatment medicine for regulating and controlling glucose metabolism reprogramming. The theaflavin can be specifically and directly combined at a UGP2 active site in a targeting manner through high activity to inhibit the activity of the UGP2, is the first specific inhibitor which takes the UGP2 as a target spot and is reported at present, and can be used for remarkably inhibiting tumor phenotypes such as proliferation, migration and invasion of liver cancer cells by inhibiting UGP2-mediated UDPG synthesis and intracellular glycogen accumulation.

The invention discloses application of a theaflavin compound in preparation of a medicine for inhibiting beta amyloid peptide aggregation, and belongs to the technical field of biological medicine. Multi-dimensional experiments prove that the galloyl group in the theaflavin compound can significantly inhibit the formation of Abeta42 amyloid fibers, reduce the generation of toxic oligomers and reconstruct formed oligomers by increasing binding sites with Abeta42 polypeptide and enhancing polar interaction and hydrophobic interaction. The TF3 (containing two galloyl groups) has the optimal anti-Abeta 42 polypeptide aggregation activity, a precise target spot is provided for design of an Abeta amyloid aggregation inhibitor taking the galloyl groups as a core structure, and an experimental basis is provided for application of a natural polyphenol compound in preparation of a medicine for preventing or treating Alzheimer's disease.

The invention relates to a dibenzotropol ketone theaflavin derivative as well as a preparation method and application thereof, and belongs to the field of heterocyclic compounds. The preparation method comprises the following steps: taking pear homogenate as an enzyme source, carrying out step-by-step enzymatic oxidation in a phosphate buffer solution, oxidizing EGC and ECG to generate an intermediate TF-3 '-G and a dibenzotropol ketone theaflavin derivative 1, and reacting the TF-3'-G with EC to generate a dibenzotropol ketone theaflavin derivative 2. The preparation process is mild in condition and high in directionality, and the product is obtained through ethyl acetate extraction, column chromatography purification and ethanol gradient elution. The prepared dibenzotropol ketone theaflavin derivative has an excellent alpha-amylase inhibition effect, the inhibition rates of the derivative 1 and the derivative 2 are respectively increased by 9.5 times and 5.1 times compared with those of acarbose, and the dibenzotropol ketone theaflavin derivative has a good prospect in the field of preparation of alpha-amylase inhibitors.

The invention discloses a collagen dressing and a preparation method thereof, and relates to the technical field of collagen dressings, and the collagen dressing comprises a dressing loaded on a gel-non-woven fabric composite carrier. According to the collagen dressing and the preparation method thereof provided by the invention, I / III type collagen compounding and small molecule peptide synergistic infiltration promotion, theaflavin-alginate oligosaccharide-trehalose ternary active matter intelligent stability maintenance, nano-encapsulation targeted delivery and gel-non-woven fabric composite carrier dynamic attachment are performed; the wound healing is accelerated, the scar rate is reduced, the transdermal rate of active ingredients is multiplied, the dressing change is free of damage, and the limitation that a traditional dressing is slow in repairing, many in scar and high in adhesion is broken through.

The present invention relates to an emulsifier, an emulsification composition, an oral cleansing agent, and an oral cleansing composition, each comprising at least one of theaflavin and thearubigin. The present invention also relates to an emulsification method and an oral cleansing method, each using at least one of theaflavin and thearubigin.

This invention relates to the field of black tea fermentation technology, and discloses a black tea fermentation device and method. The black tea fermentation device includes a fermentation tank, with a drive shaft rotatably connected to the center of the tank's inner cavity. Cross plates are fixedly connected to both sides of the drive shaft, and driven shafts are fixedly connected between each end of the cross plates on both sides. The device also includes multiple fermentation trays, each mounted on a driven shaft. Through gear transmission and speed increase, a piston plate is driven to slide reciprocally within a piston chamber, achieving alternating pressure reduction and pressurization for pulsating oxygen supply. During pressurization, high-pressure airflow penetrates the tea layer, forcibly providing positive pressure oxygen supply to eliminate dead zones, ensuring synchronous oxidation reactions and enhancing enzyme activity. During pressure reduction, carbon dioxide and hot, humid waste gas are rapidly discharged to prevent suffocation and heartburn. This simulates the rhythm of biological respiration, significantly promoting the formation of theaflavins and thearubigins, and optimizing biochemical reactions.

The invention provides a theaflavin composition for preventing and treating hyperuricemia as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a chicory extract, a hovenia dulcis thunb extract, a semen plantaginis extract, a poria cocos extract, a pericarpium citri reticulatae extract and a corn stigma extract. The theaflavin, the cichorium intybus extract, the hovenia dulcis thunb extract and the semen plantaginis extract are used for inhibiting the activity of xanthine oxidase and regulating the function of uric acid transporter to realize bidirectional regulation of uric acid generation and excretion aiming at the diseases of excessive uric acid generation and excretion reduction; the poria cocos extract and the pericarpium citri reticulatae extract fundamentally improve internal environment disorder through transportation and transformation functions of the spleen and the stomach, reduce generation of phlegm dampness and stasis and create good body conditions for uric acid metabolism; the corn stigma extract guides all the medicines to directly reach the disease site, enhances the concentration and action efficiency of the medicines in excretion organs, accurately positions the urinary system, and forms a multi-target all-directional synergistic treatment system of treating symptoms, treating root causes and inducing meridians.

Provided is a method for preparing a theaflavin using an immobilized substrate, including: enriching a catechin molecule substrate, a natural plant monomer, on an inert adsorption carrier in a non-covalent bonding manner; subjecting a resulting material to purification; and catalyzing polymerization of the catechin molecule substrate enriched on the carrier with a high-selectivity free exogenous enzyme to produce the dimeric substance of theaflavin. The purification and enzymatic oxidation condensation of the catechin substrate are integrated on a same carrier, which reduces the difficulty of process operations.

The application discloses a method for preparing high-purity theaflavins by using macroporous resin columns in combination, and belongs to the technical field of food engineering. A crude theaflavins solution with a purity of 15-30% is added to an LX-20B resin column, gradient elution is carried out according to a specific procedure, and after the eluate is concentrated by rotary evaporation and / or freeze-drying, a first-purification product is obtained; the first-purification product solution is added to an AB-8 resin column, gradient elution is carried out according to a specific procedure, and after the eluate is concentrated by rotary evaporation and freeze-drying, a high-purity theaflavins product with a purity of 95% or above is obtained, so that the demand for high-purity theaflavins in some high-end health product and medical research and development fields can be met, and the application range of theaflavins is widened.

Disclosed is a method for preparing high-purity theaflavins by coupling macroporous resin columns, belonging to the technical field of food engineering. A crude theaflavin solution with a purity of 15%-30% is loaded onto an LX-20B resin column and subjected to gradient elution according to a specific procedure; eluent is concentrated by rotary evaporation and / or freeze-dried to obtain a primary purified product; a solution of the primary purified product is loaded onto an AB-8 resin column and subjected to gradient elution according to the specific procedure; and eluent is concentrated by rotary evaporation and freeze-dried to obtain a high-purity theaflavins product with a purity of 95% or more, which can meet demands for high-purity theaflavins in some high-end health products and pharmaceutical research and development fields, and thus broadens an application range of theaflavins.

This invention relates to the field of tea processing technology and discloses a method for increasing the yield of theaflavins using alternating catalysis of exogenous enzymes. The exogenous enzyme is crude pear polyphenol oxidase solution, which is directly prepared from fruit. The method includes the following steps: first, tanninase is added to construct the conversion basis of the crude pear polyphenol oxidase solution; then, the crude pear polyphenol oxidase solution is added, allowing the enzymatic hydrolysis to be completed at room temperature with basic stirring without fermentation, thereby increasing the yield and quality of theaflavins. This invention enables the stepwise and directional conversion of ester-type catechins in tea polyphenol solutions into non-ester-type catechins, laying the foundation for subsequent conversion by exogenous enzymes. The conversion of exogenous enzymes does not require further fermentation and can be carried out at room temperature, resulting in a nearly two-fold increase in theaflavin yield.

This invention discloses the preparation and application of an orange-red pigment. By co-heating four theaflavins monomers or mixtures thereof with a mixture of amino acids such as L-theanine and glucose, the reaction product solution, after dilution, shows an increase in the a value and a decrease in the b value. The reaction solution, after release, is generally orange-red, gradually turning peach-pink with increasing dilution. This invention utilizes flavor substances abundant in tea leaves to simply and quickly synthesize food-grade peach-pink to orange-red solutions. These solutions can be used as coloring and flavoring additives for food and beverages, and also possess certain health benefits, indicating a promising market prospect.

The invention discloses application of theaflavin-3, 3 '-digallate in preparation of a medicine for treating multiple myeloma, and belongs to the technical field of multiple myeloma (MM). The TRIM28 inhibitor theaflavin-3, 3 '-digallate (TF3) obtained through high-throughput drug screening can effectively inhibit the E3 ubiquitinating enzyme activity of TRIM28, reduce TRIM22 degradation and down-regulate IRF4 protein expression, further significantly inhibits MM cell proliferation, can be used as a drug for treating multiple myeloma, and provides a new treatment strategy and drug target for preventing and treating multiple myeloma.

The invention provides a medicine for treating atherosclerosis and application thereof, and belongs to the technical field of cardiovascular disease treatment. The medicine consists of the function-enhanced mesenchymal stem cells and a medicinal carrier. The function-enhanced BMSCs are obtained by treating bone marrow mesenchymal stem cells with a composition of praeruptorin E, lobetyolin and theaflavin in a specific concentration ratio in a culture process. Experimental results show that the BMSCs prepared by the method have significantly enhanced migration ability and secretion function, and can effectively protect endothelial cells from damage induced by oxidized low-density lipoprotein. Animal model research further proves that the function-enhanced BMSCs can significantly inhibit the formation of atherosclerotic plaques and show a significant treatment effect.

The present invention discloses the use of theaflavin 3'-monogallate in inhibiting retinal pigment epithelial cell apoptosis and treating age-related macular degeneration (AMD), belonging to the field of biomedicine. Specifically, the invention discovers that theaflavin 3'-monogallate has the function of inhibiting retinal pigment epithelial cell apoptosis and promoting the inhibition of retinal pigment epithelial cell proliferation. Furthermore, the invention also discovers that theaflavin 3'-monogallate has the novel function of inhibiting AMD-like lesions caused by retinal pigment epithelial cell apoptosis. Therefore, it can be used to treat AMD, bringing good news to elderly blind patients in China.

This invention discloses an anti-muscle aging composition containing theaflavins (TF) from black tea extract and phytosterols, and its applications, belonging to the biomedical field. The composition consists of theaflavins (TF) and phytosterols (PS). Experimental verification showed that theaflavins at 1 μM and phytosterols at 1000 ppm exhibited a significant synergistic protective effect against D-galactose-induced senescence of C2C12 myoblasts. Experimental results also showed that the composition significantly enhanced cell viability and inhibited the accumulation of reactive oxygen species (ROS), with a cell viability synergistic coefficient of 0.034 and a ROS oxidative stress synergistic coefficient of 0.366, both demonstrating strong synergistic effects. The composition provided by this invention can be used to prepare drugs, functional foods, or nutritional supplements for the prevention, improvement, and / or treatment of muscle aging, featuring safety, high efficiency, and readily available raw materials, providing a new direction for the development of anti-muscle aging related products.

The invention discloses a compound preparation with anti-fatigue, nerve-calming, sleep-aiding and anti-aging functions and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The invention relates to a compound preparation with anti-fatigue, nerve-calming, sleep-aiding and anti-aging functions. The compound preparation mainly comprises the following raw material components: ginseng; fermenting the pomegranate extract; red date polysaccharide; lotus plumule alkali; coix seed oil; polygonatum sibiricum polyphenol; colla corii asini peptide; theaflavin; compound probiotics; according to the invention, probiotics and classic tonifying traditional Chinese medicines are scientifically matched, the bottleneck of component interaction is broken through through a'microorganism-traditional Chinese medicine 'co-fermentation technology, a'qi-blood regulation-viscera balance-cell repair' three-level action model is established, and the requirements of modern medical treatment on functional preparations are met.

The application discloses a tea characteristic component composition for reducing acrylamide in Maillard reaction, and the composition is prepared by compounding at least three of five substances, i.e., epicatechin (EC), gallocatechin (GC), catechin gallate (CG), theabrine and theaflavine, and the compounded composition has the effect of reducing acrylamide, a by-product of Maillard reaction in food. In the composition of the application, the composition composed of epicatechin (EC), gallocatechin (GC), catechin gallate (CG) and theabrine has the best effect of reducing acrylamide, a by-product of Maillard reaction, and the reduction rate of acrylamide in a simulation system can be up to 75%. The composition of the application can be applied to baked food or fried food, especially baked food such as bread, cookie, potato chip and the like.

This invention discloses a sterilization method for dairy products. The invention comprises two parts: the preparation of a composite microparticle agent and synergistic magnetic induction electric field sterilization. The composite microparticles are Fe... 2+ An aspartic acid complex serves as the outer antibacterial component, while okra mucilage, theaflavins, and chickpea defensins form the core antibacterial component, constructing a composite microparticle structure with a progressive effect from antibacterial to antibacterial action. During the sterilization process, the composite microparticles are added to liquid dairy products, stirred evenly, and then a magnetic induction electric field is activated. The magnetic induction electric field, in conjunction with the composite microparticles, achieves highly efficient killing of bacteria and spores in the dairy products. This solves the problems of interaction and poor stability between antibacterial components and dairy product components, as well as the difficulty in killing spores at low temperatures. It also reduces the destruction of nutritional components in dairy products, and the Fe in the composite microparticles... 2+ Aspartic acid and theaflavins all have certain nutritional value and are suitable for use in dairy products.

Provided is a method for preparing a high-purity theaflavin by coupling and combining macroporous resin columns, belonging to the technical field of food engineering. A crude theaflavin solution with a purity of 15%-30% is loaded onto an LX-20B resin column. Gradient elution is performed according to a specific procedure. The eluate is subjected to rotary evaporation concentration and / or freeze-drying to obtain a primary purified product. The primary purified product solution is loaded onto an AB-8 resin column. Gradient elution is performed according to a specific procedure. The eluate is subjected to rotary evaporation concentration and freeze-drying to obtain a high-purity theaflavin product with a purity of 95% or higher, which can meet the requirements of some high-end health products and fields such as medical research and development for high-purity theaflavins, and broaden the application range of theaflavins.

The present application provides a probiotic preparation and its use. The probiotic preparation of the present application comprises active ingredients and adjuvants, wherein the active ingredients comprise oxygen scavengers, organic acid producers and place holders; the adjuvants comprise flavoring agents, oligosaccharides and other additives; wherein the oligosaccharides are not lactulose, stachyose, raffinose, oligogentiobiose and oligochitosan, and the other additives are not theaflavins, ethylenediaminetetraacetic acid disodium salt and sorbic acid. The present application effectively promotes the metabolic activity of probiotics through a specific combination of adjuvants, rather than just providing physical protection or nutritional support. Experimental data show that the adjuvant combination of the present application can significantly and continuously improve the oxidation-reduction potential and Na + K + ATPase activity of probiotics. Moreover, the probiotic preparation of the present application can effectively improve functional gastrointestinal diseases and has a bidirectional regulation function, which is suitable for different intestinal motility disorders, such as diarrhea and constipation.

The invention relates to a processing method for freezing and preserving fresh swim bladders, and belongs to the technical field of marine product processing, and the processing method comprises the following steps: S1, preparing a preservative: preparing the following components in percentage by mass: 0.5-1% of sodium alginate, 0.5-2% of chitosan oligosaccharide, 2-4% of calcium chloride, 1-2% of sodium citrate, 0.01-0.1% of theaflavin and the balance of water, and performing spray drying to obtain the preservative; s2, soaking and fresh keeping: adding water into a fresh keeping agent to prepare a fresh keeping solution, and soaking the cleaned fresh swimming bladders in the fresh keeping solution for 30-60 minutes; s3, partial freezing treatment: putting the soaked fresh swim bladders at the temperature of-4 to-2 DEG C, and performing partial freezing for 5-8 hours; and S4, performing freezing storage treatment: putting the fresh swimming bladders subjected to partial freezing into a freezing warehouse at the temperature of-18 DEG C for storage. According to the method, the quality deterioration speed is effectively inhibited, the water retention performance is improved, and it is guaranteed that the fresh swim bladder achieves the rapid and lasting fresh-keeping effect.

Provided is a method for preparing theaflavins on the basis of substrate immobilization. The method comprises: enriching natural plant monomeric catechin molecular substrates on an inert adsorption carrier in a non-covalent bond manner, performing purification, and then catalyzing the polymerization of the enriched catechin substrates on the carrier into dimeric substances, i.e., theaflavins, by means of a high-selectivity free exogenous enzyme. The purification and enzymatic oxidative condensation of the catechin substrates are integrated and implemented on the same carrier, thus reducing the operational difficulty of the process.

The application provides a bio-based Mannich base, a preparation method thereof, an application thereof, and a TDI curing agent prepared by using the bio-based Mannich base as a catalyst. The bio-based Mannich base is obtained by a Mannich reaction of natural phenol, dimethylamine and formaldehyde, wherein the natural phenol is one or more selected from the group consisting of sesamol, catechin, theaflavin, daidzein and procyanidin. The Mannich base catalyst prepared by using the natural phenol in the application improves steric hindrance, and the reaction selectivity of small molecule monomers can be improved through the steric hindrance effect. The content of free TDI monomers in the TDI curing agent can be reduced by adding the catalyst at one time, so that the free monomers in the prepared TDI curing agent are less than 0.5% advantageously.